Wolverine Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Wolverine Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-964	Closed	-$2.51K	–	1946
2023 Q3	$2.51K	Sell	964 -77	-7%	-$256	﹤0.01%	1629
2023 Q2	$5.03K	Sell	1,041 -73	-7%	-$439	﹤0.01%	1476
2023 Q1	$7.34K	Sell	1,114 -469	-30%	-$4.75K	﹤0.01%	1493
2022 Q4	$17.6K	Sell	1,583 -844	-35%	-$8.5K	﹤0.01%	1547
2022 Q3	$17K	Sell	2,427 -374	-13%	-$2.52K	﹤0.01%	1866
2022 Q2	$16K	Sell	2,801 -638	-19%	-$8.38K	﹤0.01%	1878
2022 Q1	$84K	Sell	3,439 -272	-7%	-$8.85K	﹤0.01%	1360
2021 Q4	$177K	Sell	3,711 -546	-13%	-$39.4K	﹤0.01%	1247
2021 Q3	$394K	Buy	4,257 +2,308	+118%	+$300K	﹤0.01%	1025
2021 Q2	$226K	Buy	+1,949	New	+$514K	﹤0.01%	1231
2021 Q1	–	Sell	-10	Closed	-$2K	–	2189
2020 Q4	$2K	Buy	+10	New	+$1.64K	﹤0.01%	1574

Other funds holding NRXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

OWMIAS

One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Asset Management's NRXP Position: Q4 2023 in Review

Wolverine Asset Management sold out of NRX Pharmaceuticals (NRXP) in Q4 2023, closing a stake of 964 shares — an estimated $2.51K sold.

Wolverine Asset Management first reported a position in NRXP in Q4 2020 and held it in 11 quarters. The position peaked at $394K in Q3 2021. 30 funds tracked by Wall St. Rank hold NRXP as of Q4 2023.

Wolverine Asset Management reported no remaining NRX Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Wolverine Asset Management sold 964 NRX Pharmaceuticals shares in Q4 2023, an estimated $2.51K.
Wolverine Asset Management first reported a position in NRX Pharmaceuticals in Q4 2020 and held it in 11 quarters.
Wolverine Asset Management's NRX Pharmaceuticals position peaked at $394K in Q3 2021.
30 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2023.

Based on Wolverine Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.